This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Menu
WATCH ON DEMAND: Spotlight Presentationskeyboard_arrow_right

WATCH ON DEMAND: Spotlight Presentations

search

WATCH ON DEMAND: Spotlight Presentations

search
WATCH ON DEMAND: Spotlight Presentations
On Demand
Cell Therapy
Closed Systems — The Solution for the Worlds Increasing Demands on CGT
  • Jayanthi Grebin - Senior Business Development Manager CGT, CPC - Colder Products Company, USA
On Demand
Gene Edited Ex Vivo Cell Therapy
Benchtop to Bioreactor: T-cell Culture and Expansion in Chemically Defined Media
  • Supriya Pokkali - Sr. Scientist II, Research and Development Department, FUJIFULM Irvine Scientific, R&D (Cell & Gene Therapy), USA
On Demand
In Vivo Gene Therapy
Next-generation transfection reagent for large scale AAV manufacturing
  • Mathieu Porte - R&D Production Manager, Polyplus-transfection, France
On Demand
Cell Therapy
From Vein to Vein: How Starting Material Quality Impacts the Success of Next-Generation Therapies
  • Joy Aho - PhD, Senior Product Manager, Be The Match BioTherapies, USA
On Demand
Gene Edited Ex Vivo Cell Therapy
How to Commercially Scale T-cell Allogeneic Therapies
  • Jesse Trekker - Business Manager, Catalent Cell and Gene Therapy, Belgium
On Demand
In Vivo Gene Therapy
Commercializing Gene Therapies: From Process Development to Manufacturing
  • Rachel Legmann - Director, Gene Therapy & Viral Vectors, Pall Corporation
On Demand
Cell Therapy
Enabling the industrialization of cell and gene therapies through process development and platforms for commercial readiness
  • Hartmut Tintrup - Global Head of Business Development for CGT, Lonza Pharma & Biotech
WATCH ON DEMAND: Spotlight Presentations 12:40am - 1:00am20 mins
Gene Edited Ex Vivo Cell Therapy
Manufacturing CRISPR RNPs for Clinical Applications
  • Nicole Kavanaugh, Ph.D - Manager, Technical Operations, Aldevron, USA
On Demand
In Vivo Gene Therapy
Technology innovation for cost-effective viral vector manufacturing
  • Mohammed Elfar - Production Innovation Manager, Univercells Technologies
On Demand
Cell Therapy
Advancing ATMP’s Manufacturing: Risks and Opportunities on Next Generation Ancillary Materials
  • Claudia Zylberberg - CEO, Akron Biotech
On Demand
Gene Edited Ex Vivo Cell Therapy
Standardized Viral Vector and Plasmid Manufacturing and Analytics
  • Jeffrey Hung - Chief Commercial Officer, Vigene Biosciences, Inc., USA
On Demand
In Vivo Gene Therapy
Comparison of qPCR and ddPCR methods for the analysis of Residual DNA
  • Sumaya Dauleh - Senior Analyst, Intertek, UK
On Demand
Gene Edited Ex Vivo Cell Therapy
High yield mRNA production process from E.Coli to highly pure mRNA
  • Aleš Štrancar - CEO, BIA Separations, Slovenia
On Demand
Gene Edited Ex Vivo Cell Therapy
Accelerating Viral Vector Commercialization Through Suspension Platform with Greater Predictability
  • Steve Tottey - Associate Director, Downstream Process Development, WuXi Advanced Therapies, USA
  • Yiyu Dong - Head Cell Line Development, WuXi Advanced Therapies, USA
On Demand
Gene Edited Ex Vivo Cell Therapy
Innovative Closed Process CAR-T Cell Therapy Platform to Streamline Approach for Manufacturing with Great Predictability
  • Tatiana Golovina - Senior Director, Cell Therapy Process Development, WuXi Advanced Therapies, USA
DAY FOUR WATCH LIVE (EST); 22/10/20
Choose Day